Assessment and monitoring of biologic drug adverse events in patients with psoriasis

References

• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLFleischerABJrReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol1999413 pt 140140710459113
   PubMed Web of Science ®Google Scholar
• NICE.org.uk [webpage on the Internet]. National Institute of Clinical ExcellencePsoriasis Guidelines [updated August 2013; cited September 1, 2015]. Available from: https://www.nice.org.uk/guidance/qs40Accessed January 21, 2016
   Google Scholar
• ZachariaeHPrevalence of joint disease in patients with psoriasis: implications for therapyAm J Clin Dermatol20034744144712814334
   PubMed Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJNChair of Guideline GroupBritish Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009Br J Dermatol20091615987101919857207
   PubMed Web of Science ®Google Scholar
• Garcia-DovalICarreteroGVanaclochaFRisk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trialsArch Dermatol2012148446347022508869
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD00879421328309
   PubMed Web of Science ®Google Scholar
• KotharyNDiakILBrinkerABezabehSAviganMDal PanGProgressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patientsJ Am Acad Dermatol201165354655121514689
   PubMed Web of Science ®Google Scholar
• BurdenADWarrenRBKleynCEThe British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectivesBr J Dermatol2012166354555422356636
   PubMed Web of Science ®Google Scholar
• IskandarIYAshcroftDMWarrenRBDemographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions RegisterBr J Dermatol2015173251051825989336
   PubMed Web of Science ®Google Scholar
• AliTKaithaSMahmoodSFtesiAStoneJBronzeMSClinical use of anti-TNF therapy and increased risk of infectionsDrug Healthc Patient Saf20135799923569399
   PubMedGoogle Scholar
• KalbREFiorentinoDFLebwohlMGRisk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)JAMA Dermatol2015151996196925970800
   PubMed Web of Science ®Google Scholar
• ReichKPappKAGriffithsCEAn update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upJ Drugs Dermatol201211330031222395580
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMERASURE Study GroupFIXTURE Study GroupSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• Sánchez-MoyaAIGarcía-DovalICarreteroGBIOBADADERM Study GroupLatent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registryJ Eur Acad Dermatol Venereol201327111366137423134268
   PubMed Web of Science ®Google Scholar
• Sánchez-MoyaAIDaudenEIncidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patientsJ Eur Acad Dermatol Venereol201125673073321564322
   PubMed Web of Science ®Google Scholar
• ErgunTSeckinDBaskan BulbulEThe risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agentsInt J Dermatol201554559459925753908
   PubMed Web of Science ®Google Scholar
• NICE.org.uk [webpage on the Internet]. National Institute of Clinical ExcellenceUstekinumab for the Treatment of Adults with Moderate to Severe Psoriasis [updated September 2009; cited September 1, 2015]. Available from: https://www.nice.org.uk/guidance/ta180Accessed January 21, 2016
   Google Scholar
• TsaiTFHoVSongMPHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study GroupsThe safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infectionBr J Dermatol201216751145115222803615
   PubMed Web of Science ®Google Scholar
• TsaiT-FBlauveltAFoxTGongYHuangJSecukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis: a pooled phase 3 safety analysisJ Am Acad Dermatol2015725AB251
   Web of Science ®Google Scholar
• NastAGisondiPOrmerodADEuropean S3-Guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version – EDF in cooperation with EADV and IPCJ Eur Acad Dermatol Venereol201529122277229426481193
   PubMed Web of Science ®Google Scholar
• Sanz-BuenoJVanalclochaFGarcia-DovalIRisk of reactivation of Hepatitis B virus infection in Psoriasis Patients Treated with Biologics: A retrospective analysis of 20 cases from the BIOBADADERM databaseActas Dermo-sifiliograficas2015106647747225776200
   PubMedGoogle Scholar
• MohanAKCotéTRBlockJAManadanAMSiegelJNBraunMMTuberculosis following the use of etanercept, a tumor necrosis factor inhibitorClin Infect Dis200439329529915306993
   PubMed Web of Science ®Google Scholar
• NICE.org.uk [webpage on the Internet]. National Institute of Clinical ExcellenceSecukinumab for Treating Moderate to Severe Plaque Psoriasis [updated July 2015; cited September 1, 2015]. Available from: https://www.nice.org.uk/guidance/ta350Accessed January 21, 2016
   Google Scholar
• SivamaniRKGoodarziHGarciaMSBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoringClin Rev Allergy Immunol201344212114022311162
   PubMed Web of Science ®Google Scholar
• PaiMZwerlingAMenziesDSystematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an updateAnn Intern Med2008149317718418593687
   PubMed Web of Science ®Google Scholar
• GarcovichSRuggeriAD’AgostinoMClinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational studyJ Eur Acad Dermatol Venereol201226121572157621923840
   PubMed Web of Science ®Google Scholar
• LaffitteEJanssensJPRoux-LombardPTuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs tuberculin skin testBr J Dermatol2009161479780019659473
   PubMed Web of Science ®Google Scholar
• TagmoutiSSlaterMBenedettiAReproducibility of interferon gamma (IFN-γ) release assays. A systematic reviewAnn Am Thorac Soc20141181267127625188809
   PubMedGoogle Scholar
• NICE.org.uk [webpage on the Internet]National Institute of Clinical Excellence: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control [updated March 2011; cited September 1, 2015]. Available from: https://www.nice.org.uk/guidance/cg117Accessed January 21, 2016
   Google Scholar
• SolovicISesterMGomez-ReinoJJThe risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementEur Respir J20103651185120620530046
   PubMed Web of Science ®Google Scholar
• DommSCinatlJMrowietzUThe impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literatureBr J Dermatol200815961217122818945310
   PubMed Web of Science ®Google Scholar
• WHO.int [webpage on the Internet]. World Health OrganisationHepatitis B [updated July 2015; cited September 1, 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/Accessed January 21, 2016
   Google Scholar
• AhnCSDothardEHGarnerMLFeldmanSRHuangWWTo test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritisJ Am Acad Dermatol2015733420.e428.e26184440
   PubMed Web of Science ®Google Scholar
• MotaparthiKStanisicVVan VoorheesASLebwohlMGHsuSMedical Board of the National PsoriasisFrom the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasisJ Am Acad Dermatol201470117818624220724
   PubMed Web of Science ®Google Scholar
• Pérez-AlvarezRDíaz-LagaresCGarcía-HernándezFBIOGEAS Study GroupHepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 casesMedicine (Baltimore)201190635937122033451
   PubMed Web of Science ®Google Scholar
• CassanoNMastrandreaVPrincipiMAnti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic diseaseJ Biol Regul Homeost Agents201125228528921880218
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345151098110411596589
   PubMed Web of Science ®Google Scholar
• PompiliMBiolatoMMieleLGriecoATumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature reviewWorld J Gastroenterol201319447867787324307780
   PubMed Web of Science ®Google Scholar
• CostaLCasoFAttenoMLong-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patientsClin Rheumatol201433227327623975363
   PubMed Web of Science ®Google Scholar
• NavarroRVilarrasaEHerranzPSafety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical settingBr J Dermatol2013168360961622985451
   PubMed Web of Science ®Google Scholar
• RyanCLeonardiCLKruegerJGAssociation between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsJAMA2011306886487121862748
   PubMed Web of Science ®Google Scholar
• GottliebABKalbRELangleyRGSafety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesJ Drugs Dermatol201413121441144825607786
   PubMed Web of Science ®Google Scholar
• HughJVan VoorheesASNijhawanRIFrom the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapiesJ Am Acad Dermatol201470116817724184141
   PubMed Web of Science ®Google Scholar
• TzellosTKyrgidisAZouboulisCCRe-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trialsJ Eur Acad Dermatol Venereol201327562262722404103
   PubMed Web of Science ®Google Scholar
• ChungESPackerMLoKHFasanmadeAAWillersonJTAnti-TNF Therapy Against Congestive Heart Failure InvestigatorsRandomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trialCirculation2003107253133314012796126
   PubMed Web of Science ®Google Scholar
• MannDLMcMurrayJJPackerMTargeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)Circulation2004109131594160215023878
   PubMed Web of Science ®Google Scholar
• MahilSKAndrewsTCBrierleyCBarkerJNSmithCHDemyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literatureJ Dermatolog Treat2013241384922268700
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter studyThe Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupNeurology199953345746510449104
   PubMed Web of Science ®Google Scholar
• SegalBMConstantinescuCSRaychaudhuriAUstekinumab MS InvestigatorsRepeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging studyLancet Neurol20087979680418703004
   PubMed Web of Science ®Google Scholar
• PouplardCBrenautEHorreauCRisk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studiesJ Eur Acad Dermatol Venereol201327suppl 3364623845151
   PubMed Web of Science ®Google Scholar
• DommaschEDAbuabaraKShinDBNguyenJTroxelABGelfandJMThe risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trialsJ Am Acad Dermatol20116461035105021315483
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJBuchanIMattesonELMontoriVAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA2006295192275228516705109
   PubMed Web of Science ®Google Scholar
• RaaschouPSimardJFNeoviusMAsklingJAnti-Rheumatic Therapy in Sweden Study GroupDoes cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agentsArthritis Rheum20116371812182221305513
   PubMed Web of Science ®Google Scholar
• StrangfeldAHierseFRauRRisk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Res Ther2010121R520064207
   PubMed Web of Science ®Google Scholar
• MercerLKLuntMLowALRisk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for rheumatoid arthritisAnn Rheum Dis20157461087109324685910
   PubMed Web of Science ®Google Scholar
• Le BlayPMouterdeGBarnetcheTMorelJCombeBRisk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studiesClin Exp Rheumatol201230575676422766000
   PubMed Web of Science ®Google Scholar
• DuguePAReboljMGarredPLyngeEImmunosuppression and risk of cervical cancerExpert Rev Anticancer Ther2013131294223259425
   PubMed Web of Science ®Google Scholar
• KimSCGlynnRJGiovannucciERisk of high-grade cervical dysplasia and cervical cancer in women with systemic inflam-matory diseases: a population-based cohort studyAnn Rheum Dis20157471360136724618265
   PubMed Web of Science ®Google Scholar
• AllegrettiJRBarnesELCameronAAre patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysisInflamm Bowel Dis20152151089109725895005
   PubMed Web of Science ®Google Scholar
• van LümigPPDriessenRJRoelofs-ThijssenMABoezemanJBvan de KerkhofPCde JongEMRelevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumabBr J Dermatol2011165237538221428975
   PubMed Web of Science ®Google Scholar
• Pfizer [webpage on the Internet]Summary of Product Characteristics: Etanercept [cited September 1, 2015]. Available from: https://www.medicines.org.uk/emc/medicine/19162Accessed January 21, 2016
   Google Scholar
• AbbVie [webpage on the Internet]Summary of Product Characteristics: Adalimumab [cited September 1, 2015]. Available from: https://www.medicines.org.uk/emc/medicine/21201Accessed January 21, 2016
   Google Scholar
• GisondiPCazzanigaSChimentiSPsocare Study GroupMetabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare RegistryJ Eur Acad Dermatol Venereol2013271e30e4122313340
   PubMed Web of Science ®Google Scholar
• PinkAEFoniaAAllenMHSmithCHBarkerJNAntinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational studyBr J Dermatol201016278078519863499
   PubMed Web of Science ®Google Scholar
• BogasMLeandroMJBiologic therapy and pregnancy. A systematic literature reviewActa Reumatol Port201136321923222113598
   PubMed Web of Science ®Google Scholar
• CasanovaMJChaparroMDomènechESafety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel diseaseAm J Gastroenterol2013108343344023318480
   PubMed Web of Science ®Google Scholar
• ChambersCDJohnsonDLEmerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancyBirth Defects Res A Clin Mol Teratol201294860761122786755
   PubMed Web of Science ®Google Scholar
• VerstappenSMKingYWatsonKDSymmonsDPHyrichKLBSRBR Control Centre Consortium, BSR Biologics RegisterBSRBR Control Centre Consortium BSRBR. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics RegisterAnn Rheum Dis201170582382621362710
   PubMed Web of Science ®Google Scholar
• YiuZZGriffithsCEWarrenRBSafety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patientsBr J Dermatol2014171348549124749725
   PubMed Web of Science ®Google Scholar
• AdelzadehLJourabchiNWuJJThe risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditionsJ Eur Acad Dermatol Venereol201428784685225081573
   PubMed Web of Science ®Google Scholar
• SalemiSPicchianti-DiamantiAGermanoVInfluenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicityClin Immunol2010134211312019846344
   PubMed Web of Science ®Google Scholar
• BrodmerkelCWadmanELangleyRGImmune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab useJ Drugs Dermatol201312101122112924085047
   PubMed Web of Science ®Google Scholar